Latham lawyers discuss how recent developments may impact FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

The initial months of the Trump administration have been marked by a flurry of executive orders and activity by the Department of Government Efficiency (DOGE). Those efforts, along with a recent Office of Management and Budget memorandum, may lead to drastic changes at the US Food and Drug Administration (FDA).

In this episode of Connected With Latham, Washington, D.C. partners Chris Schott and Ben Haas and associate Danny Machado explore how FDA may be affected by these developments, particularly with regard to novel tobacco and nicotine products, which can be a bellwether for approval and enforcement trends more generally.

Listen here or subscribe via Apple Podcasts, Spotify, or anywhere else you listen to podcasts.

See all episodes in our Drug Pricing series here.